EI
AVIR icon

EAM Investors’s Atea Pharmaceuticals AVIR Stock Holding History

EAM Investors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-112,866
Closed -$607K – 279
2026
Q1 		$607K Buy
+112,866
New +$518K 0.07% 252

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EAM Investors's AVIR Position: Q2 2026 in Review

EAM Investors sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 112,866 shares — an estimated $607K sold.

EAM Investors first reported a position in AVIR in Q1 2026 and held it in 1 quarter. The position peaked at $607K in Q1 2026. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • EAM Investors reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 112,866 Atea Pharmaceuticals shares in Q2 2026, an estimated $607K.
  • EAM Investors first reported a position in Atea Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • EAM Investors's Atea Pharmaceuticals position peaked at $607K in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.